Otago Innovation

Amaroq Therapeutics is a biotechnology company that develops cancer therapies targeting long non‑coding RNAs, a recently discovered class of RNA molecules. The company’s platform is based on research originating from the University of Otago in Dunedin, New Zealand, and it focuses on treating common solid tumours such as breast, colorectal and liver cancer. By using long non‑coding RNAs as therapeutic targets and diagnostic markers, Amaroq aims to create next‑generation treatments that improve patient outcomes.